Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Medtronic Neuromodulation
483
•Medtronic Neuromodulation•January 21, 2011

Medtronic Neuromodulation – FDA 483, Jan 21, 2011

Record Details

An FDA inspection conducted at Medtronic Neuromodulation, located in Minneapolis, MN, from November 17, 2010, to January 21, 2011, identified five significant observations documented in Form FDA-483. These observations highlight deficiencies in the company's quality system, particularly concerning the Synchromed II Drug Delivery System.The primary issues included inadequate process validation for the Synchromed II system, where various process changes and additions were implemented without proper qualification or re-qualification. Additionally, design validation for the Synchromed II was found insufficient, with discrepancies between units used for validation and those in production, and out-of-specification data in qualification records.Further observations noted deficiencies in complaint handling procedures. Returned products were not analyzed promptly, leading to inaccurate hazard coding and affecting product trending data. Numerous Product Comment Reports (PCRs) lacked accurate hazard codes or reference to corrective and preventive actions (CAPA), and some were not assigned for investigation. Finally, the documentation of CAPA activities and results was inadequate, specifically regarding motor stall issues in the Synchromed II and EL Pump, where identified mitigation actions were not implemented or justified. Design input requirements for Synchromed II were also not adequately documented, lacking verifiable details and showing discrepancies between specifications and testing.Medtronic Neuromodulation acknowledged these observations and "promised to correct" each identified deficiency, indicating a commitment to address the quality system shortcomings.

Company
Medtronic Neuromodulation
Inspection date
January 21, 2011
Product type
devices
Office
Minneapolis District Office
People
  • Thomas M. Tefft (Vice President)
  • Susan M. Atcher
  • Jessica L. Johnson
View Company Profile

ID · 7e95409e-32e3-484c-8da1-1e86ce0604f4

Other documents for Medtronic Neuromodulation
  • 483 - 2023-05-05May 5, 2023
  • EIR - 2023-05-05May 5, 2023
  • 483 - 2022-11-03November 3, 2022
  • 483 - 2019-10-17October 17, 2019
  • 483 - 2017-06-30June 30, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Medtronic Neuromodulation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.